(AGENPARL) – mer 27 novembre 2024 9TH ANNUAL MEETING
NEW TECHNOLOGIES
AND STRATEGIES
TO FIGHT CANCER
REGGIO EMILIA
under the auspices of
o rga n i z e d by
November 28-30, 2024
Centro Internazionale
Loris Malaguzzi – RE
COMMITTEES
LOCAL
COMMITTEE
Massimo Boni
Ilaria Tonelli
Alessia Ciarrocchi
Antonio Curti
Milena Fini
Toni Ibrahim
Giovanni Martinelli
Francesco Merli
Oriana Nanni
Antonino Neri
Nicola Normanno
Maria Abbondanza Pantaleo
Carmine Pinto
Paolo Giorgi Rossi
Katia Scotlandi
Marco Seri
Paola Ulivi
ORGANIZING
SECRETARIAT
SCIENTIFIC
COMMITTEE
Vincenzo Bronte
Ruggero De Maria
Lucia Del Mastro
Milena Fini
Silvia Franceschi
Lisa Licitra
Franco Locatelli
Giovanni Martinelli
Antonino Neri
Nicola Normanno
Pier Giuseppe Pelicci
Marco Seri
Giovanni Tonon
ORGANIZING
COMMITTEE
PRESIDENT
Antonino Neri
MI&T srl – Provider n. 1509
Viale Carducci 50
40125 Bologna
http://www.mitcongressi.it
PROGRAM
DAY 1 / 28/11/2024
14.00-14.30
WELCOME ADDRESSES OF THE AUTHORITIES
Ruggero De Maria – President, Alliance Against Cancer
Maria Rosaria Campitiello – Head of the Department of Prevention,
Research, and Health Emergencies | Ministry of Health
Marco Massari – Mayor of Reggio Emilia
Cristina Marchesi – General Director of IRCCS Reggio Emilia
Carlo Adolfo Porro – Dean of the University of Modena
and Reggio Emilia
14.30-14.45
OPENING REMARKS
Antonino Neri
14.45-16.00
SCIENTIFIC SESSION
HOW THE TANGO BETWEEN GENETICS
AND PLASTICITY IS RESHAPING ONCOLOGY
Chairs: Pier Giuseppe Pelicci – Giovanni Tonon
Aula 1
16.00-17.15
Studying melanoma evolution one cell at the time
Jean-Christophe Marine
Mutations in normal oesophagus give insight
into chemotherapy resistance
Phil Jones
Phenotypic states of metastatization and drug-resistance
Pier Giuseppe Pelicci
Early and late responses to cancer therapy mount distinct
drug-induced tolerance states
Giovanni Tonon
SCIENTIFIC SESSION
CELL THERAPY
Chairs: Concetta Quintarelli – Francesca Bonifazi
Aula 1
Novel approaches on the use of CAR T cells
in patients with cancer
Franco Locatelli
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
Innate-like CAR T cells
Paolo Dellabona
How can we predict which NHL patients can benefit more
from CAR T cells
Paolo Corradini
17.15-17.45
Coffee Break
17.45-18.15
Lectio Magistralis
Introduction: Marco Seri
The role of TFEB-mTORC1 signaling in inherited cancer syndromes
Andrea Ballabio
18.15-19.30
SCIENTIFIC SESSION
NOVEL INSIGHTS IN CANCER:
FROM MECHANISMS TO THERAPY
Chairs: Marco Seri – Marco Alessandro Pierotti
Aula 1
RASopathies: the other face of RAS signaling upregulation
Marco Tartaglia
The Warburg effect in cancer
Gerry Melino
Extracellular vesicles: novel theranostics tools in cancers
Angela Toss
DAY 2 / 29/11/2024
8.30-10.00 ORAL COMMUNICATIONS
Aula 1
CANCER BIOMARKERS
Chairs: Maurizio D’Incalci – Anna Sapino
A novel fusion circRNA from the KMT2A::AFF1 fusion gene
in pediatric B-ALL patients and SEM cell line harboring
the t(4;11)(q21.3-q22.1;q23.3) translocation
D. Tolomeo, L. Calamo, G. Fazio, S. Venuto, G. Visci, A. Lonoce,
I. Cifola, M. Severgnini, G. Cazzaniga, C. T. Storlazzi
(Università degli Studi di Bari Aldo Moro – Bari, Italy)
Molecular landscape and tumor microenvironment features
of 5-year glioblastoma survivors: A multicenter ACC
retrospective study
S. Indraccolo, BE. Miele, E. Anghileri, E. Lazzarini, M. Patanè,
A. Ciolfi, L. Pedace, C. Nardini, S. Patrizi, A. Mastronuzzi,
M. Tartaglia, C. Calatozzolo, E. Lamperti, M. Dell’Agata, E. Pirola,
M. Scarpelli, G. Lombardi, V. Villani, M. Simonelli, R. Merli,
A. Salmaggi, F. Locatelli, B. Pollo (Istituto Oncologico Veneto –
Padua, Italy)
Comparison of different triage strategies combining cytology,
p16/ki67 and partial or extended genotyping in the Italian
NTCC2 study
P. Mancuso, M. Benevolo, G. Ronco, F. Carozzi, L. De Marco, E. Allia,
S. Bisanzi, R. Rizzolo, D. Gustinucci, A. Del Mistro, H. Frayle,
M. Confortini, J. Viti, A. Iossa, E. Cesarini, S. Bulletti,
B. Passamonti, S. Gori, L. Toniolo, L. Bonvicini, F. Venturelli,
N. Wentzensen, P. Giorgi Rossi, NTCC2 Working Group
(AUSL-IRCCS di Reggio Emilia – Italy)
The Follicle Stimulating Hormone Receptor (FSHR) is a universal
tumor antigen for early diagnosis and therapy of solid tumors:
special focus on Triple-Negative Breast Cancer
D. Carpanese, V. Rossi, A. Turati, A. Tosi, A. Penna, G. Zuccolotto,
C. Bolzati, M. Saviano, A. Giorgio, A. Del Gatto, L. Zaccaro,
A. Rosato (Istituto Oncologico Veneto – Padua, Italy)
Early diagnosis of High Grade Serous Ovarian Cancer through
genomic instability analysis of DNA from the PAP test smears
S. Marchini, L. Paracchini, L. Mannarino, R. Zadro, L. Beltrame,
P. Zola, R. Frusico, L. Bocciolone, D. Lorusso, F. Raspagliesi,
L. Giordano, V. Canzonieri, M. D’Incalci
(IRCCS Humanitas Research Hospital – Rozzano, Italy)
Prognostic Significance of Baseline Total Metabolic Tumor
Volume in Follicular Lymphoma: A sub-study of FOLL12 trial
R. Durmo, S. Chauvie, F. Bergesio, F. Fallanca, L. Marcheselli,
M. Federico, A. Versari, L. Guerra, S. Luminari, On Behalf of FOLL12
Trial Research Group (AUSL-IRCCS di Reggio Emilia – Italy)
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
Is the message in the bottle? Evaluating clonal coverage of liquid
biopsies within triple-negative breast cancer
D. Ceresa, B. Cardinali, A. Daga, R. Tasso, A. Sciutto, I. Appolloni,
D. Marubbi, F. Carli, P. Fregatti, P. Malatesta, L. Del Mastro
(IRCCS Ospedale Policlinico San Martino – Genoa, Italy)
A peculiar chromosome 17 copy number profile stratifies
HER2-low breast carcinomas
S.E. Bellomo, E. Berrino, L. Casorzo, I. Sarotto, C. Parlato,
S. Guarrera, A. Botticelli, R. Ponzone, A. Sapino, N. Crosetto,
C. Marchiò (Candiolo Cancer Institute – Candiolo, Italy)
Aula 2
NOVEL THERAPEUTIC APPROACHES IN CANCER
TREATMENT
Chairs: Lucia Del Mastro – Giovanni Martinelli
Improved Adoptive T Cell Therapies for Colorectal Liver
Metastases by Stabilization of IFNAR1 on Tumor-Specific T-Cells
A. Castiglioni, C. Giordano, G. Delfanti, P. Zordan, I. Stefanetta,
L. M. Ferreira, A. Monestriroli, F. Caruso, C. Fagioli, B. Clissi,
C. B. Ekalle-Soppo, A. Esposito, C. Gnasso, H. Abken, A. Brendolan,
L. Guidotti, G. Casorati, P. Dellabona, G. Sitia
(San Raffaele Research Hospital – Milan, Italy)
Adoptive immunotherapy with T lymphocytes targeting
the HER2 antigen offers new hope for treating patients
with Osteosarcoma and Ewing’s Sarcoma
M. Aurigemma, C. Quintarelli, M. G. Milano, A. Ottaviani,
M. Guercio, M. Becilli, F. Del Bufalo, A. Mastronuzzi, A. Paiardini,
F. Locatelli, B. De Angelis (Ospedale Pediatrico Bambino Gesù –
Rome, Italy)
CAR T-cell Therapy Targeting B7-H3 in Medulloblastoma
A. Ottaviani, R. Ciccone, M. Pezzella, L. Iaffaldano, S. Manni,
A. Sarcinelli, P. De Falco, A. Camera, M. Sinibaldi, S. Di Cecca,
S. Caruso, F. Del Bufalo, M. Ceccarelli, G. Del Baldo, A. Mastronuzzi,
C. Bottino, R. Castriconi, C. Quintarelli, F. Locatelli, B. De Angelis
(Ospedale Pediatrico Bambino Gesù – Rome, Italy)
Exploiting hyaluronan as a natural and effective immunological
adjuvant for protein based vaccines against HER2 expressing
breast cancer
V. Rossi, D. Carpanese, A. Dalla Pietà, B. Genova, I.M. Montagner,
A. Penna, G. Zuccolotto, A. Grigoletto, G. Pasut, A. Rosato
(Istituto Oncologico Veneto – Padua, Italy)
Preclinical efficacy of a HER2 synNotch/CEA-CAR
combinatorial immunotherapy against colorectal cancer
with HER2 amplification
M. Cortese, E. Torchiaro, A. D’Andrea, F. Invrea, L. Franco, C. Donini,
V. Leuci, S. M. Leto, V. Vurchio, F. Cottino, C. Isella, S. Arena,
E. Vigna, A. Bertotti, L. Trusolino, D. Sangiolo, E. Medico
(Candiolo Cancer Institute – Candiolo, Italy)
A feasible alternative to CD19-CAR T lymphocytes:
The Potential of Cytokine-Induced Killer (CIK) cells combined
with Anti-CD19/20 antibodies
E. Cappuzzello, R. Sommaggio, E. Vigolo, G. D’Accardio,
H. Trong Ngo, P. Palmerini, M. Peipp, A. Rosato (Istituto Oncologico
Veneto – Padua, Italy)
NanoPhages: Engineered Viral Vectors for Receptor Targeted
Photodynamic Therapy
M. Calvaresi, L. Ulfo, P. E. Costantini, R. Saporetti, M. Di Giosia,
E. Turrini, A. Danielli (IRCCS Azienda Ospedaliero-Universitaria
di Bologna – Bologna, Italy)
Exploring ephrin receptors in Osteosarcoma: integrating
transcriptomics and 3D bioprinted models to advance
therapeutics
A. Puce, L. Ciuffreda, A. Massacci, C. Bonomo, V. Laquintana,
M. Pallocca, I. Terrenato, R. Covello, R. Biagini, S. Soddu,
C. Gargioli, G. Ciliberto, V. Ferraresi, R. Loria (Istituto Nazionale
Tumori Regina Elena – Rome, Italy)
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
Aula 3
TECHNOLOGICAL ADVANCES IN CANCER DIAGNOSTICS
AND TRANSLATIONAL RESEARCH
Chairs: Milena Fini – Enzo Medico
Sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents
ejection fraction reduction, reduces myocardial and renal NF-κB
expression and systemic pro-inflammatory biomarkers in models
of short-term doxorubicin cardiotoxicity
V. Quagliariello, N. Maurea, A. Paccone, F. Izzo, I. Giacobbe,
M. Barbato, V. Giordano, R. Arianna, M. Iovine, A. Caronna,
A. Bonelli, G. Palma, A. Luciano, F. Bruzzese, F. Zito Marino,
M. Montella, R. Franco, M. Berretta (Istituto Nazionale TumoriIRCCS-Fondazione G. Pascale – Naples, Italy)
Technical and organizational solutions for research molecular
findings data collection: the FPG500 molecular database
T. Pasciuto, I. Mozzetta, P. Casu, G. Placidi, G. Bravetti, R. Nilo,
F. De Angelis, L. Giacò, A. Panfili, S. Duranti, A. Minucci, G. Tortora,
C. Nero, G. Scambia (Research core Facility Data Collection GSTeP
– Fondazione Policlinico Universitario “A. Gemelli” – Rome, Italy)
MOREOVER: multiomics MR-guided radiotherapy optimization
in locally advanced rectal cancer
L. Boldrini, G. Chiloiro, S. Di Franco, A. Romano, L. Smiljanic,
E. Huong Tran, F. Bono, D. Charles Davies, L. R. Lopetuso,
M. De Bonis, A. Minucci, L. Giacò, D. Cusumano, L. Placidi,
D. Giannarelli, E. Sala, M. A. Gambacorta (Fondazione Policlinico
Universitario “A. Gemelli” – Rome, Italy)
Role of the Interferon alpha inducible protein 6 (IFI6)
in establishing chemoresistance in Acute Myeloid Leukemia
S. Frascolla, S. Milovanovic, A. Cossa, G. Perticari, Y. Zhan, T. Vlachou,
P. G. Pelicci (Istituto Europeo di Oncologia – Milan, Italy)
The ACC RECORD study: development and validation
of radiomics-based predictive modelling for locally advanced
rectal cancer using multicentric “real-world data”
L. Boldrini, E. Huong Tran, G. Chiloiro, A. Petrillo, R. Fusco,
V. Granata, A. Palmisano, M. Mori, A. Esposito, M. A. Gerardi,
M. Cremonesi, V. Giannini, A. Defeudis, L. Sorrentino, R. Vigorito,
G. R. D’Agostino, E. Palazzari, E. Menghi, R. Sghedoni, F. Bono,
E. Sala, M. A. Gambacorta (Fondazione Policlinico Universitario
“A. Gemelli” – Rome, Italy)
HFE H63D variant promotes epithelial to mesenchymal transition
of pancreatic cancer in cell-cycle dependent manner
F. Rubbino, L. Greco, A. Di Cristofaro, V. de Murtas, A. Scagliotti,
G. De Simone, S. Forciniti, F. Grizzi, P. Bianchi, G. Basso,
S. Marchini, L. Lambroia, P. Kunderfranco, F. Gavazzi, P. Cappello,
F. Novelli, C. Doglioni, M. Falconi, A. Zerbi, A. Malesci, L. Laghi
(IRCCS Humanitas Research Hospital – Rozzano, Italy)
Organoid-based platform of Triple-Negative Breast Cancer
to study immunotherapy response: a single-centre experience
(STARLET study)
E. Gasparini, M. Ragazzi, G. Manzotti, A. Bisagni, F. Torricelli,
V. Manicardi, C. Ascione, E. Zanetti, E. Begnini, S. Coiro, G. Ferrari,
G. Bisagni, C. Pinto, A. Ciarrocchi, F. Reggiani (AUSL-IRCCS
di Reggio Emilia – Italy)
Killing senescent cells by targeting lysosomes: in vitro evidence
for a novel one-two punch approach in anaplastic thyroid cancer
B. Mazzoleni, M. Mazzoni, A. Greco (Fondazione IRCCS Istituto
Nazionale dei Tumori – Milan, Italy)
10.00-11.15 SCIENTIFIC SESSION
DIGITAL HEALTH AND REAL-WORD UNIVERSE IN CANCER
Chairs: Silvia Franceschi – Paolo Giorgi Rossi
Aula 1
Pragmatic trials and big data, the case
of multicancer test screening
Peter Sasieni
Biomedical imaging, artificial intelligence and what lies in the middle
Luca Boldrini
AI and Big Data in oncological research.
Regulatory constraints and possible ways forward
Giusella Finocchiaro
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
Aula 2
SCIENTIFIC SESSION
ACC IN THE DEVELOPMENT OF THE REGIONAL
ONCOLOGY NETWORK
Chairs: Gennaro Ciliberto – Carmine Pinto
The evolution of Regional Oncology Network in Italy
Manuela Tamburo De Bella
Innovation and research in the Regional Oncology Network
Ruggero De Maria
The patients in the Italy and in Europe programmes
Francesco De Lorenzo
SCIENTIFIC SESSION
DNA REPAIR SYSTEM AND CANCER THERAPY:
THE FUTURE OF PARPi IN CANCER CARE
Aula 3
PARPi and innovation in gynecologic cancer therapy
Domenica Lorusso
The evolution of PARPi
Romano Danesi
A new strategy in prostate cancer
Giuseppe Procopio
11.15-11.45
Coffee Break
Chairs: Alfredo Budillon – Gustavo Baldassarre
11.45-13.15 SCIENTIFIC SESSION
CHANGING PARADIGMS IN MANAGEMENT
OF LYMPHOMAS R
Chairs: Francesco Merli – Manlio Ferrarini
Aula 1
Use of genomics in the management of lymphomas
Davide Rossi
New computational models for lymphoma diagnosis
and therapeutic prediction
Sabino Ciavarella
The evolving use of PET in Lymphomas
Stefano Luminari
Novel agents in the treatment of Lymphomas
Pier Luigi Zinzani
Aula 2
SCIENTIFIC SESSION
UNMET CLINICAL NEEDS IN HETEROGENEOUS
RARE TUMORS: SARCOMAS
Chairs: Toni Ibrahim – Franca Fagioli
Embracing the complexity of osteosarcoma through genetic
characterization of tumors and experimental models
Katia Scotlandi
Novel mechanisms of cancer development in visceral
mesenchimal tumors
Maria Abbondanza Pantaleo
How to study an heterogeneous rare cancer?
Paolo Giovanni Casali
SCIENTIFIC SESSION
NOVEL THERAPEUTIC APPROACHES IN CANCER
Aula 3
Targeting FLT3 in acute leukemias:
from mutations to TAD-driven overexpression
Anna Ferrari
Deciphering Dynamics: Integrating Peripheral and In-Situ Tumor
Ecosystems with Cell Therapy-Based Approaches
Marcella Tazzari
Molecular Dissection of brain tumors: what’s new
Enrico Franceschi
Novel Perspectives on Theranostics
Federica Matteucci
13.15-14.15
Lunch
Chair: Nicola Normanno
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
14.15-15.45 ORAL COMMUNICATIONS
Aula 1
CANCER OMICS
Chairs: Luca Mazzarella – Federica Torricelli
Accuracy of RENOVO predictions on variants
reclassified over time
L. Mazzarella, E. Bonetti, G. Tini
(Istituto Europeo di Oncologia – Milan, Italy)
Familial predisposition in myeloproliferative neoplasms:
an NGS-driven analysis
F. Ramundo, L. Di Marino, R. Maggi, T. Malara, M. Rossi, F. Fosso,
S. Betti, E. Rossi, S. Sica, V. De Stefano, P. Chiusolo
(Fondazione Policlinico Universitario “A. Gemelli” – Rome, Italy)
The pro-metastatic phenotype of chemoresistant breast cancer
is stable and transcriptionally defined
A. Dalmasso, A. Cossa, I. Servidio, E. Bugani, G. Campani,
F. A. Tucci, N. Roda, S. Pece, P.G. Pelicci (Istituto Europeo
di Oncologia – Milan, Italy)
Characterization of EGLN1 as a pro-oncogenic factor
and pharmacological target in lung cancer
G. Verna, S. Strocchi, V. Fantini, A. Grieco, G. Santandrea,
E. Zanetti, D. Nicoli, M. Paci, A. Ciarocchi, V. Sancisi (AUSL-IRCCS
di Reggio Emilia – Italy)
Effect of genetic alterations in shaping immune profiling
in Malignant Pleural Mesothelioma
F. Torricelli, B. Donati, C. Ascione, F. Lococo, R. Piro, M. Paci,
G. Manzotti, F. Reggiani, A. Ciarrocchi (AUSL-IRCCS
di Reggio Emilia – Italy)
Molecular mimicry of SARS-COV-2 antigens as a possible cancer
vaccine strategy
M. Tagliamonte, C. Ragone, A. Mauriello, B. Cavalluzzo, B. Cembrola,
S. Mangano, L. Russo, E. Cavalcanti, L. Buonaguro (Istituto
Nazionale Tumori-IRCCS-Fondazione G. Pascale – Naples, Italy)
The chromatin remodeling hells: the missing link between
transcription and genome stability in T-Cell Lymphoma
V. Fragliasso, S. Mallia, G. Gambarelli, V. Manicardi, F. Torricelli,
E. Vitale. B. Donati, S. Muccioli, M. Zanelli, A. Neri, S. Luminari,
A. Ciarocchi (AUSL-IRCCS di Reggio Emilia – Italy)
RUNX2 supports Thyroid Cancer metastasis by reprogramming
cell metabolism
E. Vitale, M. Gugnoni, V. Manicardi, S. Muccioli, E. Salviato,
M. Tigano, A. Ciarrocchi (AUSL-IRCCS di Reggio Emilia – Italy)
Aula 2
TUMOR MICROENVIRONMENT
Chairs: Antonio Curti – Alessandro Sgambato
Multiplex spatial phenotyping identifies microglial CD147 as
a potential mediator of CD8+ T cell exclusion in ependymoma
D. Lucchetti, F. Toma, T. Servidei, F. Colella, M. Gessi, A. D’ Amati,
L. Giacò, A. Sgambato (Università Cattolica del Sacro Cuore –
Rome, Italy)
Role of IL12-Family Cytokines and Their Receptors in the
Mechanisms of Selection, Survival, and Expansion of Chronic
Lymphocytic Leukemia Cells
N. Bertola, F. Ferrero, E. Nano, M. Cardillo, M. Colombo, R. Massara,
M. C. Capra, A. Ibatici, E. Angelucci, F. Morabito, F. Fais, M. Ferrarini,
S. Ravera, G. Cutrona (IRCCS Ospedale Policlinico
San Martino – Genoa, Italy)
FLT3 Mutational Status is associated with differences in Acute
Myeloid Leukemia immune transcriptomic profile impacting on
response to FLT3 Inhibitors
J. Nanni, J. Vadakekolathu, L. Bandini, M. Ciciarello, K. Volkava,
S. Bruno, V. Robustelli, L. Zannoni, C. Sartor, G. Cristiano,
F. Zingarelli, A. Romagnoli, C. Azzimondi, F. Ardizzoia, R. Ciruolo,
G. Marconi, C. Venturi, A. Kanapari, G. Mazzocchetti, G. Simonetti,
M. Ghetti, N. Testoni, S. Parisi, S. Paolini, S. Soverini, E. Ottaviani,
C. Papayannidis, M. Cavo, S. Rutella, A. Curti (Istituto di Ematologia
«L. e A. Seràgnoli» – IRCCS AOU di Bologna – Bologna, Italy)
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
Autophagy inhibition as a novel combination strategy to target
FLT3-mutated leukemic stem cells under conditions mimicking
the hypoxic bone marrow microenvironment.
S. Bruno, C. Mosca, M. Mancini, D. Forte, S. De Santis, C. Monaldi,
M. Cavo, S. Soverini (Istituto di Ematologia «L e A. Seràgnoli» IRCCS AOU di Bologna – Bologna, Italy)
Unravelling platelets-cancer cells interaction triggered
by TGFβ in a breast cancer model
D. Schiroli, M. Genitoni, A. Razzoli, G. Gavaioli, L. Merolle,
R. Baricchi, C. Marraccini (AUSL-IRCCS di Reggio Emilia – Italy)
Loss of ATGL promotes enhanced mitochondrial respiration
and aggressiveness in triple-negative breast cancer (TNBC)
T. Rossi, N. Lorito, A. Gianferrari, A. Ciarrocchi, A. Morandi,
M. Pistoni (AUSL-IRCCS di Reggio Emilia – Italy)
Gene expression profiling identifies a protective role of B-cells
during progression of Classical Hodgkin Lymphoma
B. Donati, T. Lazic, M.E. Nizzoli, A. Ferrari, S. Pozzi, R. Durmo,
A. Gennaro, A. Ruffini, R. Valli, C. Ascione, A. Versari, F. Merli,
A. Ciarrocchi, S. Luminari (AUSL-IRCCS di Reggio Emilia – Italy)
Harnessing NK Cell Potential Against NSCLC
V. Fantini, Reggiani, A. Grieco, F. Torricelli, S. Strocchi, G. Verna,
A. Ciarrocchi, V. Sancisi (AUSL-IRCCS di Reggio Emilia – Italy)
Aula 3
HEALTH CARE MODELS AND PATIENT MANAGEMENT
IN CANCER
Chairs: Stefania Gori – Paolo Pedrazzoli
The unment needs of cancer survivors in the Ausl Irccs Reggio
Emilia: a qualitative study
S. Costi, A. Contri, L. Ghirotto
(AUSL-IRCCS di Reggio Emilia – Italy)
The incidence of tumors in under 50s in Northern Italy:
a population based study
L. Mangone, F. Marinelli, I. Bisceglia, F. Roncaglia, F. Morabito,
C. Testa, C. Pinto, A. Neri (AUSL-IRCCS di Reggio Emilia – Italy)
Risk-based cervical cancer screening: from evidence
generation to the development of Italian recommendations
on the use of biomarkers in screening programmes
F. Venturelli, P. Mancuso, S. Gori, A. Del Mistro, D. Gustinucci,
L. De Marco, S. Bisanzi, M. Benevolo, P. Giorgi Rossi, the NTCC2
Working group, the Multi-society Italian Guidelines for Cervical
Cancer Prevention Working Group
(AUSL-IRCCS di Reggio Emilia – Italy)
Depression, Hopelessness, and Suicidal Behavior in Oncology
Patients: Clinical Predictors
C. Calderoni, E. De Chiara, A. Restaino, G. Sani, A. Simonetti
(Fondazione Policlinico Universitario “A. Gemelli” – Rome, Italy)
Stakeholder Engagement to inform the implementation
of the national lung cancer screening program in Italy
O. Djuric, F. Venturelli, E.C. Ivanciu, P. Mantellini, G. Gorini,
P. Giorgi Rossi (AUSL-IRCCS di Reggio Emilia – Italy)
An experience of co-creation to reduce inequalities in cervical
cancer screening
L. Bonvicini, G. Iorio, L. Ghirotto, N. Auzzi, M. Bardou, R. Buus Bøje,
P. Kirkegaard, P. Giorgi Rossi (AUSL-IRCCS di Reggio Emilia – Italy)
Cancer patients who will be cured and projections of complete
prevalence to 2030 in Italy
L. Dal Maso, F. Toffolutti, F. Giudici, S. Francisci, R. De Angelis,
L. Botta, S. Guzzinati (Centro di Riferimento Oncologico
di Aviano IRCCS – Aviano, Italy)
Adjuvant systemic therapy in Early Breast Cancer and results
of a prospective observational multicenter BRIDE study: outcome
of the patients and adherence to guidelines in clinical practice
A. Modena, S. Gori, A. Fabi, C. Angiolini, M. Turazza, P. Salvini,
G. Ferretti, E. Cretella, L. Gianni, C. Bighin, A. Toss, C. Zamagni,
P. Vici, C. De Rossi, A. Russo, G. Bisagni, A. Frassoldati, L. Borgato,
A. Cariello, C. Cappelletti, R. Bordonaro, S. Cinieri, M. Valerio,
M. Verzè, M.F. Alvisi, I. De Simone, F. Galli, E. Rulli, A. Santoni,
F. Nicolis (IRCCS Sacro Cuore Don Calabria Hospital –
Negrar di Valpolicella, Italy)
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
15.45-17.15
WORKING GROUP MEETINGS
17.15- 17.45
Coffee Break
17.45-19.15
POSTER SESSION
DAY 3 / 30/11/2024
8.30-10.15
SCIENTIFIC SESSION
Chairs: Vincenzo Bronte – Paolo Marchetti
Aula 1
The evolving immune ecosystem of pancreatic cancer
Vincenzo Bronte
High dimensional resolution of the malignant pleural Mesothelioma
ecosystem: new perspective of therapy
Alessia Ciarrocchi
A gene therapy strategy to reprogram the tumor microenvironment
towards inducing and supporting protective immune responses
Luigi Naldini
Germinal Center Biology shapes B-Cell Lymphoma Ecosystems
and Clinical Outcomes
Claudio Tripodo
TUMOR ECOSYSTEMS
10.15-10.45
Lectio Magistralis
Introduction: Antonino Neri
Innate Immunity, Inflammation and Cancer: double edged swords
Alberto Mantovani
10.45- 11.15
Coffee Break
11.15-12.15
ACC PROJECT & ACTIVITIES
Aula 1
Chairs: Lisa Licitra – Lucia Del Mastro
The HBD program
Pier Giuseppe Pelicci
Cancer in Europe
Giovanni Apolone
The Accord Project
Luca Mazzarella
The Precision Project
Enzo Medico
12.15-13.15
BEST SELECTED ORAL COMMUNICATIONS
Chairs: Ruggero De Maria – Antonino Neri
The role of Natural Killer cells in promoting immunotherapy
efficacy in Triple-Negative Breast Cancer patients: a novel
opportunity for therapeutic intervention
F. Reggiani, G. Manzotti, E. Gasparini, A.R. Redavid, V. Manicardi,
E. Salviato, F. Torricelli, B. Donati, M. Ragazzi, A. Bisagni, C. Pinto,
A. Ciarrocchi (AUSL-IRCCS di Reggio Emilia – Italy)
Mapping functional to morphological variation reveals the basis
of regional extracellular matrix subversion and nerve invasion
in pancreatic cancer
P. Di Chiaro, L. Nacci, F. Arco, G.R. Diaferia, G. Natoli
(Istituto Europeo di Oncologia – Milan, Italy)
Adoptive cell therapy with cytokine-induced killer cells armed
with immunotools against her-2 expressing breast cancer.
R. Sommaggio, H. Trong Ngo, E. Cappuzzello, E. Vigolo,
G. D’Accardio, G. Griguolo, P. Palmerini, M. Peipp, A. Rosato
(Istituto Oncologico Veneto – Padua, Italy)
Harnessing memory stem T cells for adoptive immunotherapy
of cancer
G. Inchingolo, L. Gattinoni, J. Kochenderfer, J. Brudno, E. Lugli,
L. Biasco (Leibniz Institute for Immunotherapy – Regensburg,
Germany)
13.15-13.30
CLOSING REMARKS
Antonino Neri – Ruggero De Maria
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
FACULTY
Giovanni Apolone, Milano
Gustavo Baldassarre, Aviano
Andrea Ballabio, Napoli
Luca Boldrini, Roma
Francesca Bonifazi, Bologna
Vincenzo Bronte, Padova
Alfredo Budillon, Napoli
Paolo Giovanni Casali, Milano
Alessia Ciarrocchi, Reggio Emilia
Sabino Ciavarella, Bari
Gennaro Ciliberto, Roma
Paolo Corradini, Milano
Antonio Curti, Bologna
Romano Danesi, Milano
Francesco De Lorenzo, Roma
Ruggero De Maria, Roma
Lucia Del Mastro, Genova
Paolo Dellabona, Milano
Maurizio D’Incalci, Milano
Franca Fagioli, Torino
Anna Ferrari, Meldola
Manlio Ferrarini, Genova
Milena Fini, Bologna
Giusella Finocchiaro, Bologna
Silvia Franceschi, Aviano
Enrico Franceschi, Bologna
Paolo Giorgi Rossi, Reggio Emilia
Stefania Gori, Negrar
Toni Ibrahim, Bologna
Phil Jones, Cambridge (UK)
Lisa Licitra, Milano
Franco Locatelli, Roma
Domenica Lorusso, Milano
Stefano Luminari, Reggio Emilia
Alberto Mantovani, Milano
Paolo Marchetti, Roma
Jean-Christophe Marine, Liège (BE)
Giovanni Martinelli, Meldola
Federica Matteucci, Meldola
Luca Mazzarella, Milano
Enzo Medico, Torino
Gerry Melino, Roma
Francesco Merli, Reggio Emilia
Luigi Naldini, Milano
Oriana Nanni, Meldola
Antonino Neri, Reggio Emilia
Nicola Normanno, Meldola
Maria Abbondanza Pantaleo, Bologna
Paolo Pedrazzoli, Pavia
Pier Giuseppe Pelicci, Milano
Marco Alessandro Pierotti, Milano
Carmine Pinto, Reggio Emilia
Giuseppe Procopio, Milano
Concetta Quintarelli, Roma
Davide Rossi, Bellinzona (SVI)
Anna Sapino, Candiolo
Peter Sasieni, London (UK)
Katia Scotlandi, Bologna
Marco Seri, Bologna
Alessandro Sgambato, Roma
Manuela Tamburo De Bella, Roma
Marco Tartaglia, Roma
Marcella Tazzari, Meldola
Giovanni Tonon, Milano
Federica Torricelli, Reggio Emilia
Angela Toss, Modena
Claudio Tripodo, Milano
Paola Ulivi, Meldola
Pier Luigi Zinzani, Bologna
CONFERENCE VENUE
CENTRO INTERNAZIONALE LORIS MALAGUZZI
Viale B. Ramazzini, 72/a, 42124 Reggio Emilia
By framing the following QR code you can quicky give information
to your navigator
HOW TO REACH THE VENUE
BY CAR
Exit the motorway at Reggio Emilia, take the “tangenziale”
ing-road, direction Modena, take exit 3 “Aeroporto di Reggio Emilia”.
Parking
Parcheggio Piazzale Europa
Piazzale Europa, 42124 Reggio Emilia.
BY TRAIN
Arriving at the Central Station, take the pedestrian underground passage,
and exit in Piazzale Europa.
BY BUS
For bus routes and timetables >>>
BY High Speed “AV” TRAIN
Arriving at the AV Mediopadana Station take bus no. 5 (Direction:
Rivalta Peep) or M-Shuttle to Central Station. Take the pedestrian
underground passage and exit in Piazzale Europa.
BY PLANE
Bologna Airport is 68 KM from the Venue.
The Airport is connected with the Bologna Centrale Train Station
by Marconi Express.
Please follow this link to get more information
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
GENERAL INFORMATION
OFFICIAL LANGUAGE
English. Simultaneous translation will not be provided.
The CME event will take place in person.
The event has been accredited by the Italian Ministry of Health for 3,3 CME Credits, ID 431523
The CME Provider is MI&T srl (ID 1509).
ITALIAN CME CREDITS
Only registered participants will receive CME credits
Medical specialties:
• Biology
• Medical Radiology Technician
• Nurse
• Biomedical Laboratory Health Technician
Surgeon:
• Allergology and Clinical Immunology; Dermatology dnd Venereology; Hematology;
Endocrinology; Gastroenterology; Medical Genetics; Geriatrics; Respiratory Diseases;
Internal Medicine; Nephrology; Neurology; Oncology; Pediatrics; Radiotherapy; General
Surgery; Thoracic Surgery; Gynecology and Obstetrics; Neurosurgery; Otorhinolaryngology;
Urology; Pathological Anatomy; Anesthesiology and Resuscitation; Pharmacology and Clinical
Toxicology; Medical Genetics Laboratory; Legal Medicine; Nuclear Medicine; Clinical Pathology
(Chemical-Clinical Analysis and Microbiology Laboratory); Radiology; Pediatrics (Primary Care
Pediatricians); Hospital Medical Directorship; Palliative Care.
CME INSTRUCTIONS
To qualify for CME Credits, participants are required to attend
at least 90% of the accredited sessions and the detection of the presence
and the compilation of the satisfaction questionnaire of the event will also
be mandatory. The deadline for the completion of the CME assessment
questionnaire is set within 72 hours from the end of the course.
The Satisfaction questionnaire of the event will be available online
by accessing our platform in the “My courses” section of your reserved area.
REGISTRATION
Registration is free of charge for ACC Members.
Please complete the process to register at http://www.alleanzacontroilcancro.it
Registration fee is € 305,00 (including VAT) for Not ACC Members.
BADGES
Upon registration you will receive your personal kit and badge. All participants and exhibitors
are kindly requested to wear thei badge throughout congress in order to be admitted to the
scientific session and other scheduled activities.
CERTIFICATE OF ATTENDANCE
Certificates of attendance will be sent by email at the end of the conference.
POSTER SESSIONS
The abstract selected for poster presentations will be displayed in the Poster Area on November
29th from 17:45 to 19:15
PROVIDER CME & ORGANIZING SECRETARIAT
MI&T SRL – Provider N. 1509
Viale Giosue’ Carducci, 50
40125 Bologna
Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024
The largest Italian
cancer research network
alleanzacontroilcancro.it
THANKS TO:
GOLD SPONSOR
SILVER SPONSOR

BRONZE SPONSOR
The largest Italian
cancer research network
alleanzacontroilcancro.it
THANKS TO:
GOLD SPONSOR
SILVER SPONSOR
BRONZE SPONSOR

Alliance Against Cancer
9th Annual Meeting
November 28-30, 2024